US 2022/0089719 A1Published application

Constructs targeting labyrinthin or a portion thereof and uses thereof

AssigneeLabyRx Immunologic Therapeutics (USA) Limited

InventorsMichael BABICH, James A. RADOSEVICH

Life of this patent

Estimating the term…

Abstract

Constructs comprising an antibody moiety that specifically binds to Labyrinthin or a portion thereof and an effector domain are provided. Also provided are methods of making and using these constructs and compositions thereof.

Claims32

Dependent claims

An isolated anti-Labyrinthin construct comprising an antibody moiety that specifically binds to Labyrinthin or a portion thereof and an effector domain.

Dependencies are inferred from the claim text.

Facts

Application: 17/309,955Filed 7 Jan 2020
Priority: 8 Jan 2019
Published: 24 Mar 2022
Term ends: Not estimatedThe source records don’t support an estimate.

Classification14 codes

C07K 16/28
Against material from animals or humans: against receptors, cell surface antigens or cell surface determinants
C07K 16/30
Against receptors, cell surface antigens or cell surface determinants: from tumour cells
A61K 35/17
Blood; Artificial blood: lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
C12N 5/0636
Cells from the blood or the immune system: t lymphocytes

Family

Application62/789,871Us provisional application · filed 8 Jan 2019
US 2022/0089719 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results